This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Efficacy and tolerability of Sotrovimab, Molnupiravir and Nirmatrelvir/Ritonavir for non-hospitalized patients at high risk for COVID-19: a retrospective, single-center analysis. (preprint)
researchsquare; 2023.
Preprint
in English
| PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-2786240.v1
ABSTRACT
Background The use of outpatient antiviral treatment for high-risk patients with coronavirus disease 19 (COVID-19) is crucial in preventing progression to severe COVID-19 and reducing hospitalization rates. Objective The main goal of this retrospective, single-center analysis was to assess the feasibility and potential clinical impact of an outpatient administration of various available antiviral agents including sotrovimab (SOT), nirmatrelvir/ritonavir (N/R), molnupiravir (MOL) to COVID-19 patients at high risk for disease progression. In addition, hospital admission rates between groups. side effects and subjective treatment effects were assessed. Methods We conducted a retrospective analysis on 2606 outpatient individuals with mild to moderate COVID-19 at risk for disease progression, hospitalization, or death. After receiving either SOT (420/2606), MOL (1788/2606) or N/R (398/2606), patients were followed- up with regard to primary (hospitalization rate) and secondary (treatment and side effects) outcomes by phone. Result A total of 2606 patients were treated at the outpatient clinic, of whom 420 were treated with SOT, 398 with N/R and 1788 with MOL. 10 patients (3.2%) who were treated with SOT were later hospitalized and 1 patient had to be admitted to the ICU. In comparison, 11 patients (0.8%) who received MOL were admitted to hospital (2 admissions to the intensive care unit (ICU). No hospital/ICU admission was registered for patients who received N/R. In contrast, 46 patients (14.3%) who received N/R reported strong to severe side effects, exceeding SOT with 2.6% of the patients (8 patients in total) and MOL with 5% (69 patients) reporting strong to severe side effects. A reduction in COVID symptoms after the medication administration was experienced by 43% (132 patients) in the SOT group, 43% (572 patients) in the MOL group and 67% (115 patients) in the N/R group, respectively. In over 60-year-olds and chronic kidney disease, no subjective symptom improvement is to be expected with MOL. Women have a 1.2 elevated chance of symptom improvement with treatment with MOL. Conclusion Hospitalization rates in high-risk patients who received SOT, MOL or N/R were low, particularly in patients who received N/R. All antiviral drugs were well tolerated, but side effects were more frequent in patients with N/R. However, N/R showed the greatest subjective treatment effect.
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-RESEARCHSQUARE
Main subject:
Coronavirus Infections
/
Death
/
COVID-19
Language:
English
Year:
2023
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS